背景:帕金森病(PD),老年人的第二大神经系统疾病,表现出独特的运动障碍,包括运动迟缓,静止性震颤,和刚度。有了进步的课程,目前的治疗策略主要针对症状缓解。藏红花是一种从藏红花干柱头中分离出的化合物,并证明了神经保护特性。
目的:本研究探讨了藏红花素对PD患者运动障碍和神经元氧化DNA损伤的影响。
方法:以随机,失明,和对照试验,这项研究集中于30至80岁的特发性PD患者。使用运动障碍社会统一的PD评定量表(MDS-UPDRS)的第二部分和第三部分,在8周干预前后,我们对日常生活活动和运动障碍方面进行了评估.藏红花素组的患者每天两次接受含有30mg藏红花素的胶囊。此外,测定8-羟基-2-脱氧二鸟苷(8-OHdG)与尿肌酐比值(8-OHdG/uCr),以评估神经元氧化DNA损伤.
结果:在最初评估的164名患者中,30人被随机分配到每组,53名受试者完成研究。组内分析显示,干预8周后,MDS-UPDRS的第二部分和第三部分显着改善(P<0.05)。然而,8-OHdG/uCr无明显变化.良好耐受的每日剂量60mg藏红花素显示最小的副作用。
结论:本研究确立了藏红花素在增强日常生活活动和减轻运动障碍方面的功效。提示其作为辅助干预与传统PD药物的潜力。
BACKGROUND: Parkinson\'s disease (PD), the second most prevalent neurological disorder in the elderly, manifests with distinctive movement disorders, including bradykinesia, resting tremor, and stiffness. With a progressive course, current treatment strategies primarily target symptomatic relief.
Crocin is a chemical compound isolated from the dry stigma of Crocus sativus, and has demonstrated neuroprotective properties.
OBJECTIVE: This study explores the impact of
crocin on movement disorders and neuronal oxidative DNA damage in PD patients.
METHODS: Conducted as a randomized, blinded, and controlled trial, this research focused on patients aged 30 to 80 with idiopathic PD. Using the second and third parts of the movement disorder society-unified PD rating scale (MDS-UPDRS), aspects of daily life activity and movement disorders were assessed before and after an 8-week intervention. Patients in the
crocin groups received capsules containing 30 mg of
crocin twice daily. Additionally, the 8-hydroxy-2-deoxydiguanosine (8-OHdG) to urinary creatinine ratio (8-OHdG/uCr) was measured to evaluate neuronal oxidative DNA damage.
RESULTS: Out of the initially evaluated 164 patients, 30 were randomly assigned to each group, with 53 subjects completing the study. Within-group analysis revealed a significant improvement in the second and third parts of MDS-UPDRS after 8 weeks of crocin intervention (P < 0.05). However, the 8-OHdG/uCr did not show significant changes. The well-tolerated daily dose of 60 mg of
crocin demonstrated minimal side effects.
CONCLUSIONS: This study establishes the efficacy of
crocin in enhancing daily life activities and mitigating movement disorders, suggesting its potential as a supplementary intervention alongside conventional PD medications.